Literature DB >> 29319370

Association between CD226 polymorphism and soluble levels in rheumatoid arthritis: Relationship with clinical activity.

Youssef M Mosaad1, Ehab Es El-Toraby2, Ziyad Me Tawhid1, Adel I Abdelsalam2, Asmaa F Enin2, Amany Me Hasson2, Ghada M Shafeek3.   

Abstract

OBJECTIVE: To study the relation between CD226 rs763361 gene polymorphism and CD226 serum level and to evaluate their role in susceptibility and disease activity of RA in a cohort of Egyptian individuals.
METHODS: The serum level of CD226 was measured using a suitable ELISA kit and the CD226 rs763361 gene polymorphism was typed by PCR-RFLP for 112 RA patients and 100 healthy controls.
RESULTS: Significant association with RA was found with CD226 T allele (OR (95%CI) = 1.6 (1.04-2.4), P = 0.032), and higher CD226 serum level (P = 0.001). Higher CD226 levels were associated with higher ESR values (P = 0.035), positive CRP (0.048), increased number of tender joints (P = 0.045), and higher DAS score (P = 0.035). Serum CD226 is an independent risk factor for the prediction of RA (P = 0.001). No correlations were found between the serum level of CD226 and different CD226 genotypes and also between them and RA activity grades.
CONCLUSION: The CD226 T allele may be susceptibility risk factors for the development of RA and the higher serum level of CD226 may be involved in the pathogenesis of RA in Egyptian patients. The serum level of CD226 and not CD226 genotypes could be considered as an independent risk factor for the prediction of RA within healthy individuals and also for RA disease activity.

Entities:  

Keywords:  CD226; Egyptian; RA; RFLP; gene; polymorphism; serum

Mesh:

Substances:

Year:  2018        PMID: 29319370     DOI: 10.1080/08820139.2018.1423570

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  1 in total

1.  Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.

Authors:  Chuiwen Deng; Wenli Li; Yunyun Fei; Li Wang; Yingying Chen; Xiaofeng Zeng; Fengchun Zhang; Yongzhe Li
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.